title: Renal handling of human apolipoprotein(a) and its fragments in the rat.
abstract: The sites and mechanisms of the catabolism of atherogenic lipoprotein(a) (Lp(a)) are not well understood. Lp(a) is increased in patients with end-stage renal disease, suggesting a renal catabolism of Lp(a). To gain a better insight into renal handling of Lp(a), we established a heterologous rat model to study the renal catabolism of human Lp(a). Pure human Lp(a) was injected into Wistar rats, and animals were sacrificed at different time points (30 minutes to 24 hours). Intact Lp(a) was cleared from the circulation of injected rats with a half-life time of 14.5 hours. Strong intracellular immunostaining for apolipoprotein(a) (apo(a)) was observed in the cytoplasm of proximal tubular cells after 4, 8, and 24 hours. Apolipoprotein B (apoB) was colocalized with glomerular apo(a) 1 to 8 hours after Lp(a) injection, but renal capillaries and tubules remained negative. No relevant amounts of apo(a) fragments were found in the plasma of rats after injection of Lp(a). During all urine collection periods, apo(a) fragments with molecular weights of 50 to 160 kd were detected in the urine, however. Our results show that human Lp(a) injected into rats accumulates intracellularly in the rat kidney, and apo(a) fragments are excreted in the urine. The kidney apparently plays a major role in fragmentation of Lp(a). Despite the fact that rodents lack endogenous Lp(a), rats injected with human Lp(a) may provide a useful heterologous animal model to study the renal metabolism of Lp(a) further.
authors.affiliation: Department of Medicine, Divisions of Cardiology and Nephrology and Osteology, University Hospital Eppendorf, Hamburg, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Reblin
authors.forename: N
authors.initials: N
authors.lastname: Donarski
authors.forename: L
authors.initials: L
authors.lastname: Fineder
authors.forename: J H
authors.initials: JH
authors.lastname: Bräsen
authors.forename: H
authors.initials: H
authors.lastname: Dieplinger
authors.forename: F
authors.initials: F
authors.lastname: Thaiss
authors.forename: R A
authors.initials: RA
authors.lastname: Stahl
authors.forename: U
authors.initials: U
authors.lastname: Beisiegel
authors.forename: G
authors.initials: G
authors.lastname: Wolf
mesh_terms: D000818:Animals; D001053:Apolipoproteins / Q000008:administration & dosage / Q000378:metabolism; D001055:Apolipoproteins B / Q000378:metabolism; D053241:Apoprotein(a); D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D017270:Lipoprotein(a) / Q000008:administration & dosage / Q000378:metabolism*; D008297:Male; D023421:Models, Animal; D010446:Peptide Fragments / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001053:Apolipoproteins; D001055:Apolipoproteins B; D017270:Lipoprotein(a); D010446:Peptide Fragments; D053241:Apoprotein(a)